NCT00281827 arm group 126b8c3c093fbe104fd46b5727d90e2a [clinicaltrials_resource:NCT00281827/arm-group/126b8c3c093fbe104fd46b5727d90e2a]
thalidomide [clinicaltrials_resource:23d6d96310ed1929fa56f12c46b741ac]gemcitabine hydrochloride [clinicaltrials_resource:7ad834d04d16e4c2f305a5ca9862048e]conventional surgery [clinicaltrials_resource:bc821b2e888909e9d012463a511346ce]carboplatin [clinicaltrials_resource:d6fddbed74e7a2617fbc5e37d45d7b35]clinicaltrials:NCT00281827
arm group [clinicaltrials_vocabulary:arm-group]
NCT00281827 arm group 126b8c3c093fbe104fd46b5727d90e2a [clinicaltrials_resource:NCT00281827/arm-group/126b8c3c093fbe104fd46b5727d90e2a]
Bio2RDF identifier
NCT00281827/arm-group/126b8c3c093fbe104fd46b5727d90e2a
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 6b8c3c093fbe104fd46b5727d90e2a
description [clinicaltrials_vocabulary:description]
Chemotherapy treatment (carbop ...... ) every 21 days for 3 courses.
identifier
clinicaltrials_resource:NCT00281827/arm-group/126b8c3c093fbe104fd46b5727d90e2a
title
NCT00281827 arm group 126b8c3c093fbe104fd46b5727d90e2a
@en
type
label
NCT00281827 arm group 126b8c3c ...... b8c3c093fbe104fd46b5727d90e2a]
@en